Bristol Myers Squibb (CELG-RI) Current Deferred Tax Assets (2009 - 2015)

Bristol Myers Squibb (CELG-RI) reported Current Deferred Tax Assets of $1.7 billion for Q3 2015, up 14.64% year-over-year from $1.5 billion in Q3 2014, and down 8.51% quarter-over-quarter from $1.9 billion in Q2 2015.

Bristol Myers Squibb (CELG-RI) Current Deferred Tax Assets (2009 - 2015) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has 7 years of Current Deferred Tax Assets data on file, last reported at $1.7 billion in Q3 2015.

  • Current Deferred Tax Assets for Q3 2015 came in at $1.7 billion, up 14.64% year-over-year; the trailing twelve-month figure through Sep 2015 was $1.7 billion (up 14.64% YoY), and the FY2014 annual result was $1.6 billion, down 3.35% from the prior year.
  • Current Deferred Tax Assets fell to $1.7 billion in Q3 2015 per CELG-RI's latest filing, from $1.9 billion in the prior quarter.
  • Over five years, Current Deferred Tax Assets peaked at $2.0 billion in Q3 2013 and troughed at $1.1 billion in Q2 2011.
  • A 5-year average of $1.5 billion and a median of $1.5 billion in 2014 frame the typical range for Current Deferred Tax Assets.
  • The sharpest annual moves came in 2013 and 2014: Current Deferred Tax Assets jumped 66.81% in 2013, then slumped 30.82% in 2014.
  • A 5-year view of Current Deferred Tax Assets shows it stood at $1.2 billion in 2011, then surged by 33.08% to $1.6 billion in 2012, then rose by 6.51% to $1.7 billion in 2013, then decreased by 3.35% to $1.6 billion in 2014, then rose by 5.29% to $1.7 billion in 2015.
  • Business Quant data shows CELG-RI's Current Deferred Tax Assets at $1.7 billion in Q3 2015, $1.9 billion in Q2 2015, and $1.9 billion in Q1 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Bristol Myers Squibb - - 8.07 Bn

Historic Data

Download Data
DateValue
Sep 30, 2015 1.73 Bn
Sep 30, 2015 1.73 Bn
Jun 30, 2015 1.89 Bn
Jun 30, 2015 1.89 Bn
Mar 31, 2015 1.89 Bn
Mar 31, 2015 1.89 Bn
Dec 31, 2014 1.64 Bn
Dec 31, 2014 1.64 Bn
Sep 30, 2014 1.51 Bn
Sep 30, 2014 1.51 Bn
Jun 30, 2014 1.36 Bn
Jun 30, 2014 1.36 Bn
Mar 31, 2014 1.39 Bn
Mar 31, 2014 1.39 Bn
Dec 31, 2013 1.70 Bn
Dec 31, 2013 1.70 Bn
Sep 30, 2013 2.04 Bn
Sep 30, 2013 2.04 Bn
Jun 30, 2013 1.96 Bn
Jun 30, 2013 1.96 Bn